Vivani Medical Inc. has presented its 2025 Investor Presentation, highlighting its status as a clinical-stage biopharmaceutical company focused on the development of ultra long-acting, miniature drug implants for chronic diseases. The presentation details Vivani's NanoPortal platform technology, designed to enhance medication adherence and tolerability. Key programs include the NPM-115 (high-dose exenatide) and NPM-139 (semaglutide) implants, targeting chronic weight management with once or twice-yearly dosing. The company also discusses its IND-cleared NPM-119 (exenatide) implant for type 2 diabetes, planned for twice-yearly dosing. Anticipated milestones in 2025 include the completion of the First-in-human, LIBERATE-1 trial and advancing the NPM-139 program toward clinical development. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.